



Poster Programme

Monday, 12th September 2022

Poster Session 1

17:30-18:30

Palavela

[P1.01]

COVID-19 pandemic and routine childhood immunization in Colombia

Jose Moreno-Montoya¹, [Silvia Marcela Ballesteros](#)¹, Jaid Constanza Rojas Sotelo², Clara Lucia Bocanegra Cervera², Pedro Barrera-Lopez¹, Jose A De la Hoz-Valle¹
¹Santa Fe of Bogota Foundation, Bogotá, Colombia. ²Government of Colombia Ministry of Health and Social Protection, Bogotá, Colombia

[P1.02]

DNA vaccination against SARS-CoV-2 variants of concern: nanoparticle-mediated DNA delivery versus electroporation

[Lishan Cui](#)¹, Junbiao Wang¹, Daniela Pozzi², Erica Quagliarini², Serena Renzi², Mauro Provinciali³, Fiorenza Orlando³, Robertina Giacconi³, Marco Malavolta³, Roberta Galeazzi⁴, Luca Pesce⁵, Giulio Caracciolo², Augusto Amici^{*1}, Cristina Marchini^{*1}

¹School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy. ²Department of Chemistry, "Sapienza" University of Rome, Rome, Italy. ³Experimental Animal Models for Aging Unit, Scientific Technological Area, IRCCS INRCA, Ancona, Italy. ⁴Department of Life and Environmental Sciences, Marche Polytechnic University, Ancona, Italy. ⁵Scuola Normale Superiore di Pisa, Pisa, Italy

[P1.03]

Anti-HER2 phage-based vaccines induce therapeutic immunity against breast cancer

Junbiao Wang^{*1}, Alessia Lamolinara^{*2}, Laura Conti³, Mara Giangrossi¹, [Lishan Cui](#)¹, Federica Riccardo³, Elisabetta Bolli³, Elena Quaglino³, Federica Cavallo³, Manuela Iezzi^{*2}, Augusto Amici^{*1}, Cristina Marchini^{*1}

¹School of Biosciences and Veterinary Medicine, Biology Division, University of Camerino, Camerino, Italy. ²Aging Research Center, G. d'Annunzio University, Chieti, Italy. ³Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy

[P1.05]

Evaluation of antibody and cell-mediated immune responses against SARS-CoV-2 in mice after intramuscular administration of an RBD-based subunit vaccine

[Noemi Guerrini](#)¹, Fabrizio Anella², Francesca Dapporto¹, Livia Mazzini³, Rosa Coluccio³, Alan Chang², Vivian Yan², Emanuele Montomoli¹, Alessandro Manenti¹

¹Vismederi s.r.l., Siena, Italy. ²Taron Solutions Limited, Hong Kong, China. ³Vismederi s.r.l., Siena, Italy

[P1.06]

Evaluation of vaccine efficacy of an mRNA vaccine against SARS-CoV-2 in mouse model

[KWAGSOO LYOO](#), [Sung-Geun LEE](#), [RANHEE YOON](#)

[Jeonbuk National University, Iksan, Republic of Korea](#)

[P1.07]

Parental intention to vaccinate their children against COVID-19 in two Middle Eastern countries

[Walid Al-Qerem](#)

[Al-Zaytoonah University of Jordan, Amman, Jordan](#)

[P1.08]

Defining pathways that regulate effective generation of long-lived liver Trm cells by glycolipid peptide vaccines

[Yu Cheng Chua](#)¹, Sarah Draper², Anton Cozijnsen³, Lauren Holz¹, Geoffrey McFadden⁴, Ian Hermans^{2,5,6}, Gavin Painter^{2,6}, William Heath¹

¹Department of Microbiology and Immunology, The Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia. ²Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand. ³School of BioSciences, University of Melbourne, Melbourne, Australia. ⁴School of BioSciences, University of Melbourne, Melbourne, Australia. ⁵Malaghan Institute of Medical Research, Wellington, New Zealand. ⁶Avalia Immunotherapies Limited, Lower Hutt, New Zealand

[P1.09]

Waning effectiveness and safety of homologous primary AZD1222, CoronaVac, and BNT162b2 vaccines in the adult population in Malaysia

[Jing Lian Suah](#)¹, Norazida Ab Rahman¹, Masliyana Husin¹, Peter Seah Keng Tok¹, Thevesh Thevananthan², Boon Hwa Tng¹, Kalaiarasu Peariasamy¹, Sheamini Sivasampu¹

¹Institute for Clinical Research, National Institutes of Health, Selangor, Malaysia. ²Disease Control Division, Ministry of Health, Putrajaya, Malaysia

[P1.10]

Effectiveness of homologous and heterologous AZD1222, CoronaVac, and BNT162b2 booster vaccine against SARS-CoV-2 infection, and severe COVID-19: Comparing the Delta- and Omicron-dominant periods in Malaysia

[Jing Lian Suah](#)¹, Masliyana Husin¹, Boon Hwa Tng¹, Peter Seah Keng Tok¹, Thevesh Thevananthan², Kalaiarasu Peariasamy¹, Sheamini Sivasampu¹

¹Institute for Clinical Research, National Institutes of Health, Selangor, Malaysia. ²Disease Control Division, Ministry of Health, Putrajaya, Malaysia

[P1.11]

Effect of online education on health care provider knowledge and confidence regarding vaccine adjuvants and immunosenescence in older adults

Julia Duffey¹, [Thomas O'Neil](#)², Shanti Voorn², Stefania Maggi³, Ali M. Harandi⁴

¹Manifold Medical, Matlock, UK. ²WebMD Global LLC, New York, USA. ³CNR Aging Branch-NI, Padova, Italy. ⁴University of Gothenburg and University of British Columbia Vancouver, Gothenburg and British Columbia, Sweden

[P1.12]**New tuberculosis vaccines in India: Quantifying the potential health and economic impacts of adolescent/adult vaccination with M72/AS01E-like and BCG-revaccination-like vaccines**

Rebecca Clark¹, Christinah Mukandavire¹, [Chathika Weerasuriya](#)¹, Matthew Quaife¹, Andrew Iskauskas², Roel Bakker¹, Danny Scarponi¹, Shelly Malhotra³, Rebecca Harris^{1,4}, Nicolas Menzies⁵, Richard White¹

¹London School of Hygiene and Tropical Medicine, London, UK. ²Durham University, Durham, UK. ³International AIDS Vaccine Initiative, New York, USA. ⁴Current Address: Sanofi Pasteur, Singapore, Singapore. ⁵Harvard T.H. Chan School of Public Health, Boston, USA

[P1.13]**Understanding and evaluating the immunogenicity of a live attenuated *Salmonella* Typhimurium vaccine in aged mice**

[Jessica Allen](#), Sharon Tennant

University of Maryland, Baltimore, USA

[P1.14]**Vertical transmission of hepatitis-B decades after the international recommendation of administering hepatitis-B immunoglobulins along Hepatitis-B vaccination to newborn babies**

[Asif Rehman](#), Najibul Haq

Peshawar Medical College, Peshawar, Pakistan

[P1.15]**A novel adjuvanted vaccine for ultra-short regimen therapy of artemisia pollen-induced allergic bronchial asthma**

Kairat Tabynov^{1,2}, Meruert Babayeva^{1,3}, Tair Nurpeisov^{3,4}, Gleb Fomin¹, Temirzhan Nurpeisov⁴, Ulbossyn Saltabayeva⁵, Sankar Renu⁶, Gourapura Renukaradhya⁶, Nikolai Petrovsky^{7,8}, [Kaissar Tabynov](#)^{1,4}

¹Kazakh National Agrarian Research University, Almaty, Kazakhstan. ²M. Aikimbayev National Research Center for Especially Dangerous Infections, Almaty, Kazakhstan. ³Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan. ⁴Research Institute of Cardiology and Internal Medicine, Almaty, Kazakhstan. ⁵Astana Medical University, Nur-Sultan, Kazakhstan. ⁶The Ohio State University, Wooster, USA. ⁷Vaxine Pty Ltd, Adelaide, Australia. ⁸Flinders University, Adelaide, Australia

[P1.16]**A subunit SARS-CoV-2 spike protein oil adjuvanted vaccine provides complete protection against infection and viral transmission**

Kairat Tabynov¹, [Maxim Solomadin](#)^{1,2}, Nurbeldi Turebekov³, Meruert Babayeva¹, Gleb Fomin¹, Toktassyn Yerubayev³, Tlektes Yespolov¹, Lei Li^{4,5}, Gourapura Renukaradhya⁶, Nikolai Petrovsky^{4,5}, Kaissar Tabynov¹

¹Kazakh National Agrarian Research University, Almaty, Kazakhstan. ²Karaganda Medical University, Karaganda, Kazakhstan. ³M. Aikimbayev National Research Center for Especially Dangerous Infections, Almaty, Kazakhstan. ⁴Vaxine Pty Ltd, Adelaide, Australia. ⁵Flinders University, Adelaide, Australia. ⁶The Ohio State University, Wooster, USA

[P1.17]**Defining SARS-CoV-2 correlates of protection in non-human primates using a systems biology approach**

[Caolann Brady](#)¹, Oliver Carnell², Tom Tipton¹, Stephanie Longet¹, Karen Gooch², Javier Salguero², Adriana Tomic³, Miles Carroll¹

¹Wellcome Centre for Human Genetics and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. ²Research and Evaluation, UK Health Security Agency, Porton Down, Salisbury, UK. ³Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK

[P1.18]**Estimating health impact and cost-effectiveness of new tuberculosis vaccines in South Africa**

Christinah Mukandavire¹, Rebecca A. Clark¹, [Chathika Weerasuriya](#)¹, Roel Bakker¹, Andrew Iskauskas², Danny Scarponi¹, Armindeer Deol¹, Shelly Malhotra³, Allison Portnoy⁴, Matthew Quaife¹, Mark Jit¹, Nicolas A. Menzies⁴, Richard G White¹

¹London School of Hygiene and Tropical Medicine, London, UK. ²Durham University, Durham, UK. ³Global Access, IAVI, New York, USA. ⁴Harvard T.H. Chan School of Public Health, Baltimore, USA

[P1.19]**Egg adaptation of human H1N1 influenza virus for vaccine production**

M. Ekin Azbazdar^{1,2}, Mert Dikmenoğulları^{1,2}, [Furkan Ozan Cöven](#)³, Ayşe Nalbantsoy³, Fethiye Cöven⁴, Zeynep A. Koçer^{1,2}

¹Izmir International Biomedicine and Genome Institute, Dokuz Eylül University, 35340, Balçova, Izmir, Turkey. ²Izmir Biomedicine and Genome Center, 35340, Balçova, Izmir, Turkey. ³Department of Bioengineering, Faculty of Engineering, Ege University, 35100, Bornova, Izmir, Turkey. ⁴Bornova Veterinary Control Institute, 35100, Bornova, Izmir, Turkey

[P1.20]**Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: a phase 3, randomized, double-blind, placebo-controlled trial**

Neil Goldstein¹, [Chelsea McLean](#)¹, Auguste Gaddah², Joachim Doua², Babajide Keshinro¹, Linda Bus-Jacobs¹, Kerstin Luhn¹, Cynthia Robinson¹, Macaya Douougih¹

¹Janssen Vaccines and Prevention BV, Leiden, The Netherlands. ²Janssen Research and Development, Beerse, Belgium

[P1.21]**Examination of COVID-19 vaccines and disease in patients with chronic Hepatitis B**

Müge Toygar Deniz¹, [Sıla Akhan](#)², Muhammed Fatih Karasın²

¹Kocaeli State Hospital, Kocaeli, Turkey. ²Kocaeli University, Kocaeli, Turkey

[P1.22]**Global impact of the first year of COVID-19 vaccination: a mathematical modelling study**

Oliver Watson¹, [Gregory Barnsley](#)¹, Jaspreet Toor¹, Alexandra Hogan², Peter Winskill¹, Azra Ghani¹

¹MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK. ²School of Population Health, University of New South Wales, Sydney, Australia

[P1.23]**Evaluation of the efficiency of inactive trivalent influenza vaccine formulation against seasonal influenza**

[Furkan Ozan Cöven](#)¹, M. Ekin Azbazdar^{2,3}, Mert Dikmenoğulları^{2,3}, Zeynep A. Koçer^{2,3}, Emel Öykü Çetin Uyanıkgil⁴, Nazlı Boke Sarıkahya⁵, Nejdet Cöven⁶, Fethiye Fethiye⁶, Ayşe Nalbantsoy⁷

¹Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey. ²Izmir International Biomedicine and Genome Institute, Dokuz Eylül University, Izmir, Turkey. ³Izmir Biomedicine and Genome Center, Izmir, Turkey. ⁴Department of Pharmaceutical Technology, Faculty of Pharmacy, Ege University, Izmir, Turkey. ⁵Department of Chemistry, Faculty of Science, Ege University, Izmir, Turkey. ⁶Izmir Bornova Veterinary Control Institute, Izmir, Turkey. ⁷Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey

[P1.24]

Persistence of the SARS-CoV-2-Specific IgG at six months after vaccination with BNT162b2, BBIBP-CorV, and Gam-COVID-Vac vaccines: a longitudinal prospective study from Novi Sad, Serbia

Vladimir Petrović^{1,2}, Vladimir Vuković^{1,2}, Aleksandra Patic^{3,2}, Miloš Marković⁴, Miodjub Ristić^{1,2}

¹Department of Epidemiology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia. ²Institute of Public Health of Vojvodina, Novi Sad, Serbia. ³Department of Microbiology with Parasitology and Immunology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia. ⁴Department of Immunology, Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, Belgrade, Serbia

[P1.25]

Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes

Ayesa Syenina^{1,2}, Esther S Gan¹, Justin ZN Toh³, Ruklanthi de Alwis¹, Lowell Z Lin¹, Christine YL Tham^{1,2}, Jia Xin Yee^{1,2}, Yan Shan Leong^{1,2}, Huizhen Sam⁴, Charlene Cheong⁴, Yii Ean Teh⁴, Ian LE Wee⁴, Dorothy HL Ng⁴, Kuan Rong Chan¹, Jean XY Sim⁴, Shirin Kalimuddin⁴, Eugenia Z Ong^{1,2}, Jenny G Low^{1,2,4}, Eng Eong Ooi^{1,2,5}

¹Duke-NUS Medical School, Singapore, Singapore. ²Viral Research and Experimental Medicine Centre, Singapore, Singapore. ³Nanyang Polytechnic, Singapore, Singapore. ⁴Singapore General Hospital, Singapore, Singapore. ⁵National University of Singapore, Singapore, Singapore

[P1.26]

Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine

Christopher McMillan¹, Jovin Choo¹, Adi Idris², Aroon Supramaniam², Naphak Modhiran¹, Alberto Amarilla¹, Ariel Isaacs¹, Stacey Cheung¹, Benjamin Liang¹, Helle Bielefeldt-Ohmann^{1,3,4}, Armira Azuar¹, Dhruva Acharya², Gabrielle Kelly², Germaine Fernando^{1,5}, Michael Landsberg¹, Alexander Khromykh^{1,3}, Daniel Watterson^{1,3}, Paul Young^{1,3}, Nigel McMillan², David Muller¹

¹School of Chemistry and Molecular Biosciences, the University of Queensland, St Lucia, Australia. ²Menzies Health Institute Queensland, School of Pharmacy, Anatomy and Medical Sciences, Griffith University, Gold Coast, Australia. ³Australian Infectious Diseases Research Centre, Global Virus Network Centre of Excellence, Brisbane, Australia. ⁴School of Veterinary Science, The University of Queensland, Gatton, Australia. ⁵Vaxxas Pty Ltd, Brisbane, Australia

[P1.27]

Spike-specific T-cell responses to COVID-19 vaccines amongst children and adults with solid and haematological cancers

Amy Body^{1,2}, Elizabeth Ahern^{1,2}, Katie Lineburg³, Corey Smith³, Hesham Abdulla¹, Luxi Lal¹, Stephen Opat^{1,2}, C. Raina MacIntyre⁴, Michael Leahy⁵, Nada Hamad⁶, Bhavna Padhye⁷, Noemi Fuentes Bolanos⁸, Antoinette Anazodo⁸, Peter Downie¹, Tracey O'Brien^{9,8}, Eva Segelov^{1,2}

¹Monash Health, Melbourne, Australia. ²Monash University, Melbourne, Australia. ³QIMR Berghofer, Brisbane, Australia. ⁴The Kirby Institute, Sydney, Australia. ⁵Royal Perth Hospital, Perth, Australia. ⁶St Vincent's Hospital, Sydney, Australia. ⁷Westmead Hospital, Sydney, Australia. ⁸Sydney Children's Hospital, Sydney, Australia. ⁹Children's Cancer Institute, Sydney, Australia

[P1.30]

Safety and immunogenicity of ABNCov2, a virus-like particle based vaccine against COVID-19 in a phase 2 trial in healthy adults

Heinz Weidenthaler¹, Christine Grigat², Melanie Kolanczyk³, Eva Wagner¹, Darja Schmidt¹, Anna Stahl¹, Erika Menius⁴, Barbara Martin⁴, Laurence DeMoerloozee⁵

¹Bavarian Nordic GmbH, Martinsried, Germany. ²Clinical Research Hamburg GmbH, Hamburg, Germany. ³emovis GmbH, Berlin, Germany. ⁴Bavarian Nordic Inc., Morrisville, USA. ⁵Bavarian Nordic Switzerland AG, Zug, Switzerland

[P1.31]

Development of SARS-CoV-2 IgM after 1st vaccine dose predicts longer immunity

Chiara Piubelli¹, Alessandra Ruggiero², Lucia Calciano², Cristina Mazzi¹, Matteo Verzè¹, Sara Calder¹, Concetta Castilletti¹, Tobia Fantoni², Simone Accordini², Donato Zipeto², Zeno Bisoffi¹

¹IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella (VR), Italy. ²University of Verona, Verona, Italy

[P1.32]

Effect of SARS-CoV-2 variants on Fc-mediated antibody immunity following BNT162b2 vaccination

Ebene Haycroft¹, Ester Lopez¹, Kevin Selva¹, Samantha Davis¹, Pradhira Ramanathan¹, Adam Wheatley¹, Samuel Redmond¹, Jennifer Juno¹, Nicholas Gherardin¹, Dale Godfrey^{1,2}, Wai-Hong Tham³, Stephen Kent^{1,4}, Amy Chung¹

¹The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. ²Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Melbourne, Australia. ³The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. ⁴ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Melbourne, Australia

[P1.35]

Capturing the value of vaccination within health technology assessment and health economics

Maarten Postma¹, Eliana Biundo², Annie Chicoye³, Mark Doherty⁴, Mariia Dronova⁵, Stéphanie Garcia², Antonio J Garcia Ruiz⁶, Louis Garrison⁷, Terry Nolan⁸, David Salisbury⁹, Shazia Sheikh¹⁰, Richard Smith¹¹, Mondher Toumi¹², Juergen Wasem¹³, Ekkehard Beck²

¹University of Groningen, Groningen, The Netherlands. ²GSK, Wavre, Belgium. ³BCH CONSEILS, Neuilly-sur-Seine, France. ⁴GSK, Copenhagen, Denmark. ⁵Creative-Ceutical, Krakow, Poland. ⁶University of Malaga, Malaga, Spain. ⁷The CHOICE Institute, University of Washington, Washington, USA. ⁸University of Melbourne, Melbourne, Australia. ⁹Programme for Global Health, Royal Institute of International Affairs, Chatham House, London, UK. ¹⁰GSK, London, UK. ¹¹University of Exeter, Exeter, UK. ¹²Aix Marseille University, Marseille, France. ¹³University of Duisburg-Essen, Essen, Germany

[P1.36]

Qualitative and quantitative differences in humoral immune response induced by four SARS-CoV-2 vaccines or developed in COVID-19 convalescents

Sanda Ravlić^{1,2}, Tihana Kurtović^{1,2}, Lidija Cvetko Krajinović^{3,2}, Ana Hećimović⁴, Marija Miloš⁵, Sanja Mateljak Lukačević^{1,2}, Beata Halassy^{1,2}

¹University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Zagreb, Croatia. ²Center of Excellence for Virus Immunology and Vaccines, Zagreb, Croatia. ³University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Zagreb, Croatia. ⁴Croatian Institute of Transfusion Medicine, Zagreb, Croatia. ⁵University Hospital Centre Zagreb, Zagreb, Croatia

[P1.40]

SARS-CoV-2 neutralization assay – reliable tool for assessing therapeutic antibody quality

Sanda Ravlić^{1,2}, Ana Hećimović³, Tihana Kurtović^{1,2}, Jelena Ivančić Jelečki^{1,2}, Dubravko Forčić^{1,2}, Anamarija Slović^{1,2}, Ivan Christian Kurot^{4,2}, Željka Mačak Šafranko^{4,2}, Tatjana Mušlin³, Dina Rnjak⁵, Ozren Jakšić⁶, Ena Sorić⁶, Gorana Džepina⁷, Oktavija Đaković Rode^{8,9}, Kristina Kujavec Šljivac¹⁰, Tomislav Vuk³, Irena Jukić³, Alemka Markotić^{2,4,11,12}, Beata Halassy^{1,2}

¹Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Zagreb, Croatia. ²Center of Excellence for Virus Immunology and Vaccines (CERVirVac), Zagreb, Croatia. ³Croatian Institute of Transfusion Medicine, Zagreb, Croatia. ⁴Research Department, University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Zagreb, Croatia. ⁵Clinics for Pulmonary Diseases, University Hospital Centre Zagreb, Zagreb, Croatia. ⁶Department of Hematology, University Hospital Dubrava, Zagreb, Croatia. ⁷Department for Transfusion Medicine, University Hospital Dubrava, Zagreb, Croatia. ⁸Department for Clinical Microbiology, University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Zagreb, Croatia. ⁹School of Dental Medicine, University of Zagreb, Zagreb, Croatia. ¹⁰Clinical

[P1.42]

Supporting US healthcare providers for successful vaccine communication

Lauren Rauh, MPH, Amanda Pierz, MPH, Dima Masoud, MPH, P. Chris Palmedo, PhD, MBA, Alanna Kate Cruz, MS, Scott C. Ratzan, MD, MPA
City University of New York Graduate School of Public Health and Health Policy, New York, USA

[P1.44]

Cost-effectiveness of implementing a quadrivalent (four-strain) high-dose influenza vaccine (IIV4-HD) for older adults in Canada

Thomas Shin^{1,2}, Jason Lee^{1,3}, Bruce Seet^{1,4}, Gary Lam^{1,3}, Jianhong Wu², Fabian Alvarez⁵

¹Sanofi Canada, Toronto, Canada. ²York University, Department of Math and Statistics, Toronto, Canada. ³Leslie Dan School of Pharmacy, University of Toronto, Toronto, Canada. ⁴University of Toronto, Department of Molecular Genetics, Toronto, Canada. ⁵Sanofi, Lyon, France

[P1.45]

Natural host plurality as an overlooked parameter potentially affecting vaccine durability against RNA viruses, including SARS-CoV-2

Cleo Anastassopoulou¹, Vicky Lampropoulou¹, Gregory Poland², Athanasios Tsakris¹

¹Dept. of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. ²Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, USA

[P1.46]

Effectiveness of COVID-19 vaccines among Health Workers in Colombia: a retrospective, population-based study nested in the ESPERANZA cohort

Maryory Galvis^{1,2}, Andrés Palacios¹, Leonardo Arregocés¹, Julian Fernández^{1,3}, Mariana Pinto¹, Maylen Rojas-Botero¹

¹Ministerio de Salud y de la Protección Social, Bogotá, Colombia. ²Rijksuniversiteit Groningen, Leeuwarden, The Netherlands. ³Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA

[P1.47]

Mucosal spike-specific IgA protects against SARS-CoV-2 omicron infection.

Ulrika Marking¹, Sebastian Havervall¹, Nina Greilert-Norin¹, Wanda Christ¹, Max Gordon¹, Henry Ng¹, Kim Blom¹, Mia Phillipson², Sara Mangsbo², Anna Smed Sörensen¹, Peter Nilsson³, Sophia Hober³, Mikael Åberg², Jonas Klingström¹, Charlotte Thålin¹

¹Karolinska Institutet, Stockholm, Sweden. ²Uppsala University, Uppsala, Sweden. ³Royal Institute of Technology, Stockholm, Sweden

[P1.48]

The impact of climate crisis on healthcare and vaccine access in southeastern Louisiana during the COVID-19 pandemic

Brittany Singleton, Sara Al-Dahir, Martha Earls, Christopher Gillard

Xavier University of Louisiana - College of Pharmacy, New Orleans, USA

[P1.50]

Synergistic activity of antibodies in multivalent vaccines

Viola Viviani, Alessia Biolchi, Mariagrazia Pizza

GSK, Siena, Italy

[P1.52]

Distinct single component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling towards a potent antiviral immune response

Laura Rossmann¹, Katrin Bagola¹, Bianca Walber¹, Max Bastian², Ger Van Zandbergen¹

¹Paul-Ehrlich-Institut, Langen, Germany. ²Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany

[P1.53]

Recombinant turkey herpesvirus influenza (H9) vaccine partially overcomes maternal antibodies interference in chickens

Xue Pan^{1,2}, Qinfang Liu¹, Shiqi Niu¹, Dongming Huang¹, Qiaoyang Teng¹, Xuesong Li¹, Nancy Beerens², Maria Forlenza², Mart C.M. de Jong², Zejun Li¹

¹Shanghai Veterinary Research Institute, Shanghai, China. ²Wageningen University & Research, Wageningen, The Netherlands

[P1.54]

Replication of dengue virus in K562-megakaryocytes suppresses accumulation of reactive oxygen species and interferes with the optimum differentiation of megakaryocyte mother cell

Jaskaran Kaur¹, Yogita Rawat¹, Vikas Sood², Neha Periwal², Deepak Kumar Rathore¹, Shrikant Kumar¹, Niraj Kumar¹, Milan Surjit³, Sankar Bhattacharyya¹

¹Translational Health Science and Technology Institute, Faridabad, India. ²Jamia Hamdard University, Delhi, India. ³ranslational Health Science and Technology Institute, Faridabad, India

[P1.56]

Influenza, pneumococcal and herpes zoster vaccine uptake amongst the South African elderly in 2018

Mncengeli Sibanda^{1,2}, Johanna C Meyer^{1,2}, Natalie Schellack³, Brian Godman^{4,5}, Rosemary Burnett^{2,6}

¹Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University (SMU), Pretoria, South Africa. ²South African Vaccination and Immunisation Centre, SMU, Pretoria, South Africa. ³Department of Pharmacology, School of Medicine, University of Pretoria, Pretoria, South Africa. ⁴Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. ⁵Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University (SMU), Pretoria, UK. ⁶Department of Virology, School of Medicine, SMU, Pretoria, South Africa

[P1.57]

COVID-19 vaccine effectiveness in adolescents: a test negative case-control study in Belgium

Lucy Catteau, Toon Braeye, Léonore Nasiadka, Elias Vermeiren, Pierre Hubin, Matthieu Billuart, Veerle Stouten, Joris van Loenhout

Epidemiology and public health, Sciensano, Brussels, Belgium

[P1.58]

Association between demographic characteristics, pre-existing comorbidities and post-COVID-19 symptoms developed 12 months after the onset: A network analysis

Juan Antonio Valera-Calero¹, César Fernández-de-las-Peñas², Marcos José Navarro-Santana³, Tamara del Corral⁴, Ibai López-de-Uralde-Villanueva⁵, Gustavo Plaza-Manzano⁵

¹Camillo José Cela University, Madrid, Spain. ²Rey Juan Carlos University, Alcorcón, Spain. ³Universidad Católica de Ávila, Ávila, Spain. ⁴Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain. ⁵Universidad Complutense de Madrid, Madrid, Spain

[P1.59]

Mucosal immunization of hamsters elicits cross-reactive antibodies and decreases viral shedding following breakthrough SARS-CoV-2 infection

Molly Braun, Clarissa Martinez, Emery Dora, Laura Showalter, Sean Tucker
Vaxart, Inc, South San Francisco, USA

[P1.60]

Assessment of gold nanoparticles as carriers of a peptide-based vaccine against SARS-CoV-2

Susan Farfan-Castro¹, Omar Gonzalez-Ortega¹, Mariano Garcia-Soto¹, Rene Segura², Jacqueline Cervantes², Sergio Rosales-Mendoza¹
¹Faculty of Chemistry, Autonomous University of San Luis Potosi, San Luis Potosi, Mexico. ²National Autonomous University of Mexico Faculty of Medicine, Ciudad de México, Mexico

[P1.61]

Bacmam expressing a highly glycosylated porcine IFN- α induces robust antiviral and adjuvant effects against foot-and-mouth disease virus in pigs

Su-Mi Kim, Aro Kim, Gyeongmin Lee, Jong-Hyeon Park, Min Ja Lee
Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine Agency, Gimcheon-City, Gyeongsangbuk-do, Republic of Korea

[P1.62]

Towards the development of a semi-synthetic glycan-based vaccine against *Neisseria meningitidis*

Patricia Priegue^{1,2}, Christina Jordan³, Kathrin Siebold³, Ryan Gilmour³, Peter H. Seeberger^{1,2}
¹Max Planck Institute of Colloids and Interfaces, Potsdam, Germany. ²Freie Universität Berlin, Berlin, Germany. ³Westfälische Wilhelms-Universität Münster, Münster, Germany

[P1.63]

Immunogenicity and efficacy of an oral Zika vaccine in Zika-susceptible mice and in non-human primates (Black-Tufted Marmosets)

Andrew Bacon, Elliot Bland, Peter Bone, Craig Laferriere, Jennifer Simmons, Jeff Drew
iosBio Ltd, Haywards Heath, UK

[P1.64]

SARS-CoV-2 receptor binding domain (RBD) designs for homogeneous monomeric antigen preparations

Miriam Klausberger¹, Nikolaus Kienzl², Gerhard Stadlmayr¹, Lukas Mach², Gordana Wozniak-Knopp¹
¹Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria. ²Institute of Plant Biotechnology and Cell Biology, Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria

[P1.65]

RSV FG chimeric proteins, comprising of G protein central conserved domain without the CX3C motif, surpassed pre F vaccines in efficacy and safety

Ryo Yamaue, Madoka Terashima, Hiroaki Mori, Masaharu Torikai
KM biologics Co., Ltd, Kumamoto, Japan

[P1.66]

High-resolution flow cytometry to assess quality and immunogenicity of nano-particulate vaccines and adjuvants

Tomoya Hayashi^{1,2}, Hideo Negishi¹, Kouji Kobiyama^{1,2}, Burcu Temizoz^{1,2}, Koji Sakamoto³, Naozumi Hashimoto³, Cevayir Coban¹, Ken Ishii^{1,2}
¹The Institute of Medial Science, The University of Tokyo, Tokyo, Japan. ²National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan. ³Nagoya University Graduate School of Engineering School of Medicine, Nagoya, Japan

[P1.67]

What is the impact of genetic variation on the control of Japanese Encephalitis virus?

John Bish
NIBSC, South Mimms, UK

[P1.68]

Surveillance for a highly conserved protective epitope on hemagglutinin of H6 avian influenza virus responds to the potential zoonotic risk

Jie-Long He
Department of Post-Baccalaureate Veterinary Medicine, Asia University, Taichung, Taiwan. Laboratory Animal Center, PBVM, Asia University, Taichung, Taiwan

[P1.69]

Flu Learning Object (FLO): A novel digital decision-support aid to promote child influenza vaccination

Shih Ying Gun^{1,2}, Aminath Shiwaza Moosa^{1,2}, Ngiap Chuan Tan^{1,2}
¹SingHealth Polyclinics, Singapore, Singapore. ²SingHealth Duke-NUS Family Medicine Academic Clinical Programme, Singapore, Singapore

[P1.70]

Cost-effectiveness of a 20-valent pneumococcal conjugate vaccine to directly protect adults against pneumococcal disease in England

Diana Mendes¹, Ahuva Averin², Mark Atwood², Reiko Sato³, Andrew Vyse¹, James Campling¹, Derek Weycker², Mary Slack⁴, Gillian Ellsbury¹, Tendai Mugwagwa¹
¹Pfizer Ltd, Tadworth, UK. ²Policy Analysis Inc, MA, USA. ³Pfizer Inc, Collegeville, USA. ⁴School of Medicine & Dentistry, Griffith University, Queensland, Australia

[P1.71]

A capsid virus-like particle-based SARS-CoV-2 vaccine induces high levels of antibodies and protects rhesus macaques

Ariane Volkman¹, Gerrit Koopman², Petra Mooij², Ernst J. Verschoor², Babs E. Verstrepen², Willy M.J.M. Bogers², Manja Idorn³, Soren R. Paludan³, Soren Vang⁴, Morten A. Nielsen⁵, Adam F. Sander⁵, Carolin Schmittwolf¹, Hubertus Hochrein¹, Paul Chaplin⁶
¹Bavarian Nordic, Martinsried, Germany. ²Biomedical Primate Research Centre, Rijswijk, The Netherlands. ³University of Aarhus Department of Biomedicine, Aarhus, Denmark. ⁴Aarhus University Hospital, Aarhus, Denmark. ⁵University of Copenhagen, Copenhagen, Denmark. ⁶Bavarian Nordic, Hellerup, Denmark

[P1.72]

Effectiveness of an mRNA vaccine booster against symptomatic COVID-19 in homologous and heterologous schedules: a test-negative case-control study

Cátia Brazete^{1,2,3}, João Brazete³, Filipe Alves⁴, Marta Pinto^{4,5}, Ana Aguiar^{6,7}, Lígia Sá¹, Ana Gonçalves¹, Marta Cardoso¹, Óscar Felgueiras^{4,8,9}, Raquel Duarte^{6,4,7,10,11}
¹Unidade de Saúde Pública do Alto Minho, Viana do Castelo, Portugal. ²Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal. ³Faculdade de Medicina da Universidade do Porto, Porto, Portugal. ⁴Unidade de Investigação Clínica da Administração Regional de Saúde do Norte, Porto, Portugal. ⁵Faculdade de Psicologia e Ciências da Educação da Universidade do Porto, Porto, Portugal. ⁶EPIUnit - Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal. ⁷Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional, Porto, Portugal. ⁸Faculdade de Ciências da Universidade do Porto, Porto,

[P1.73]

Interrelationships between health, economic, and societal impacts of the COVID-19 pandemic and vaccination: An impact diagram

Kinga Marczell¹, Diana Mendes², Gabor Szabo¹, Julie Roiz³, Elizabeth Hamson², Jingyan Yang^{4,5}, Manuela Di Fusco⁴

¹Evidera Budapest, Budapest, Hungary. ²Pfizer Ltd, Tadworth, UK. ³Evidera, London, UK. ⁴Pfizer Inc, New York, USA. ⁵Institute for Social and Economic Research and Policy, Columbia University, New York, USA

[P1.74]

Preparation of a novel coronavirus-like particle vaccine candidate for preclinical trials

Alexander Jerman^{1,2}, Krista Lokar³, Tina Brecelj³, Nika Janež³, Matjaž Peterka³, Urban Bezeljak^{1,3}

¹Sferogen LLC, Ljubljana, Slovenia. ²UMC Ljubljana, Ljubljana, Slovenia. ³COBIK, Ajdovščina, Slovenia

[P1.75]

How has covid-19 pandemic changed influenza vaccination coverage among healthcare workers of IRCCS Ospedale Policlinico San Martino in Genoa?

Matilde Ogliastra¹, Elisabetta Costa¹, Rosa Amato¹, Irene Giberti¹, Carlo Simone Trombetta¹, Alexander Domnich², Laura Sticchi^{1,2}, Andrea Orsi^{1,2}, Valentino Tisa³, Paolo Durando⁴, Giancarlo Icardi^{1,2}

¹Department of Health Sciences, University of Genoa, Genoa, Italy. ²Hygiene Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. ³Medical Direction, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. ⁴Infectious Diseases Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

[P1.76]

Anti-TNF treatment in IBD patients is associated with early antibody waning indicating reduced immune memory after COVID-19 booster vaccination

Angelika Wagner¹, Erika Garner-Spitzer¹, Anna-Margarita Schötta², Maria Orola-Taus¹, Andrea Wessely¹, Peter Pichler¹, Claudia Auer¹, Lukas Weseslindtner³, Elena Tomosel¹, Maximilian Kutschera⁴, Selma Tobudic⁵, Michael Kundl⁶, Gottfried Novacek⁴, Hannes Stockinger⁷, Walter Reinisch⁴, Ursula Wiedermann¹

¹Medical University of Vienna, Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria. ²Medical University of Vienna Institute of Hygiene and Applied Immunology, Wien, Austria. ³Medical University of Vienna, Center for Virology, Vienna, Austria. ⁴Medical University of Vienna, Department of Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria. ⁵Medical University of Vienna, Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Vienna, Austria. ⁶Medical University of Vienna, Center for Public Health, Vienna, Austria. ⁷Medical University of Vienna Institute of Hygiene and Applied Immunology, Vienna, Austria

Tuesday, 13th September 2022

Poster Session 2

15:30-17:00

Palavela

[P2.01]

Impact of COVID-19 on enhanced outreach activity of vaccination and perceptions of the stakeholders in Islamabad, Pakistan

Dr. Soofia Yunus¹, Dr. Ejaz Khan², Imtiaz Hussain³, Dr. Akram Shah¹

¹Federal Directorate of Immunization, Islamabad, Pakistan. ²Health Services Academy, Islamabad, Pakistan. ³Agha Khan University, Karachi, Pakistan

[P2.02]

Delayed start of routine vaccinations in preterm and small for gestational age infants: a retrospective cohort study from Tuscany region, Italy

Vieri Lastrucci^{1,2}, Monia Puglia³, Martina Pacifici³, Franca Rusconi⁴, Primo Buscemi⁵, Giorgia Alderotti¹, Michela Sica¹, Gilda Belli⁶, Elettra Berti⁷, Fabio Voller³

¹Epidemiology Unit, Meyer Children's Hospital, Firenze, Italy. ²Department of Health Science, University of Florence, Firenze, Italy. ³Epidemiologic Observatory, Regional Health Agency of Tuscany, Firenze, Italy. ⁴Maternal and Child Department, Local Health Unit Toscana Nord Ovest, Pisa, Italy. ⁵Department of Health Science, University of Florence, Firenze, Italy. ⁶Neonatal Intensive Care Unit, Local Health Unit Toscana Centro, Firenze, Italy. ⁷Neonatal Intensive Care Unit, Meyer Children's Hospital, Firenze, Italy

[P2.03]

Effects of storage solutions on the profile of monocyte-derived dendritic cells to be used in a clinical trial for a therapeutic anti-HIV-1 vaccine

Laís Teodoro da Silva¹, Gabriela Justamante Händel Schmitz¹, Bruna Tiaki Tiyo¹, Alexandre de Almeida¹, Alberto José da Silva Duarte^{1,2}, Telma Miyuki Oshiro¹

¹Laboratorio de Investigacao Medica em Dermatologia e Imunodeficiencias (LIM 56), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil. ²Divisao de Laboratorio Central, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

[P2.04]

Tdap vaccine uptake among US adults with asthma or COPD

Sarah Naeger¹, Vitali Pool², Denis Macina³

¹Sanofi, RWE & Global Clinical Outcomes, Cambridge, USA. ²Sanofi, Vaccines Medical US, Swiftwater, USA. ³Sanofi, Vaccines Global Medical, Lyon, France

[P2.05]

COVID-19 vaccine acceptance, perceived barriers and facilitators among Peshwar population

Khalid Rehman, Imran Khan, Asif Rehman

Institute of Public Health & Social Sciences. Khyber Medical University. Peshawar. Pakistan, Peshawar, Pakistan

[P2.06]

COVID-19 vaccine hesitancy among medical and allied health sciences students in Khyber Pakhtunkhwa

Maham Zahid¹, Youhib ur rehman², Khalid Rehman¹

¹Institute of Public Health & Social Sciences. Khyber Medical University., Peshawar, Pakistan. ²Saidu medical college., Swat, Pakistan

[P2.07]

Assessment of vaccine-associated enhanced disease risk with preclinical SARS-CoV-2 vaccines in Rhesus Macaques

Cillian Gartlan¹, Tom Tipton¹, Quentin Sattentau², Andrew Gorringe³, Francisco J. Salguero³, Miles Carroll¹

¹Wellcome Centre for Human Genetics and Pandemic Sciences Institute, University of Oxford, Oxford, UK. ²The Sir William Dunn School of Pathology, University of Oxford, Oxford, UK. ³Research and Evaluation, UK Health Security Agency, Porton Down, Salisbury, UK

[P2.08]

Development of vaccine candidates for Lassa fever using Modified Vaccinia Ankara virus as a vector

Emma Kennedy, Lucy Flett, Stuart Dowall, Roger Hewson

UKHSA, Salisbury, UK

[P2.09]

"Getting the vaccine makes me a champion of it.": Understanding the motivations of australians to talk about the COVID-19 vaccines to family and friends

Joshua Karras, Holly Seale, Mia Harrison

UNSW, Sydney, Australia

[P2.10]

Application route influences the efficacy of an oncolytic virus-based cancer vaccine

Jasmin Hatami, Annika Rössler, Janine Kimpel, Zoltan Banki, Dorothee von Laer

Institute of Virology, Innsbruck, Austria

[P2.11]

Consider consumer behaviour when designing interventions to address vaccine hesitancy - evidence from South Africa

Eloise Botha¹, Daleen Van der Merwe¹, Rosemary Burnett²

¹North-West University, Potchefstroom, South Africa. ²Sefako Makgatho Health Sciences University, Pretoria, South Africa

[P2.12]

Acceptability of the Covid-19 vaccine in Senegal

Rose Nadege Mbaye¹, Ndack Diop², Mam Coumba Diouf¹, Hamidou Thiam¹, Rokhaya Diop¹, Mohamed Abass YUGO¹, Cheikh NIANG²

¹Institut Pasteur de Dakar, Dakar, Senegal. ²University Cheikh Anta Diop, Dakar, Senegal

[P2.13]

Pre-clinical evaluation through the safety and performance of vax-id® for intradermal delivery of vaccines

Koen CL Beyers, Daniele S Vasconcelos, Momen N. M. Rbeihat, Stijn Verwulgen, Vanessa V. Vankerckhoven

Idevax BV, Antwerp, Belgium

[P2.14]

Cellular and humoral immunity after the third vaccination against SARS-CoV-2 in hematopoietic stem cell transplant recipients

Laura Thümmeler^{1,2}, Michael Koldehoff^{3,4}, Neslinur Fisenkci⁵, Leonie Brochhagen², Peter Horn¹, Adalbert Krawczyk², Monika Lindemann⁵

¹Institute for Transfusionmedicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. ²Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. ³Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. ⁴Department of Hygiene and Environmental Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. ⁵Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

[P2.15]

Rapid generation of *Shigella flexneri* GMMA displaying natural or new and cross-reactive O-antigens

Gianmarco Gasperini¹, Maria Michelina Raso¹, Maria Grazia Aruta¹, Neil Ravenscroft², Barbara Bellich³, Paola Cescutti³, Francesca Necchi¹, Rino Rappuoli⁴, Francesca Micoli¹

¹GSK Vaccines Institute for Global Health, Siena, Italy. ²University of Cape Town, Rondebosch, South Africa. ³University of Trieste, Trieste, Italy. ⁴GSK Vaccines, Siena, Italy

[P2.16]

Protective antibody titers for main cat diseases – preliminary study on cats from Poland

Agnieszka Lachowicz-Wolak¹, Małgorzata Klimowicz-Bodys¹, Małgorzata Rutkowska-Szulczyk², Krzysztof Rypuła¹

¹Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland. ²Vet Planet Sp. z o. o., Łomianki, Poland

[P2.17]

Assessing the impact of COVID-19 phased vaccine eligibility on COVID-19 vaccine intent among African-Americans in Southeastern Louisiana: A community based, cohort study

Sara Al-Dahir¹, Brittany Singleton², Martha Earls¹, Christopher Gillard¹

¹Xavier University of Louisiana, New Orleans, USA. ²Xavier University of Louisiana, New Orleans, USA

[P2.18]

Pharmacists as rapid response vaccinators during a pandemic: lessons learned from the COVID-19 pandemic

Martha Earls, Brittany Singleton, Sara Al-Dahir, Christopher Gillard

Xavier University of Louisiana, New Orleans, USA

[P2.19]

An attenuated *Salmonella Gallinarum* strain is DIVA capable, safe to the environment, and protects chickens against virulent challenge

John Hwa Lee

Jeonbuk National University, Iksan, Republic of Korea

[P2.20]

Understanding baseline determinants of mRNA vaccine immunogenicity

Christine YL Tham^{1,2}, Justin SG Ooi¹, Clara WT Koh¹, Summer LX Zhang¹, Hwee Cheng Tan¹, Jenny GH Low^{1,2}, Eugenia ZY Ong¹, Kuan Rong Chan¹, Eng Eong Ooi^{1,2}

¹DUKE-NUS Medical School, Singapore, Singapore. ²Viral Research and Experimental Medicine Centre (ViREMiCS), Singapore, Singapore

[P2.21]

Phone-based survey results about perceived COVID-19 knowledge and vaccination status in the Democratic Republic of the Congo

Angelica L. Barrall¹, Dalau Mukadi Nkamba², Nicole A. Hoff¹, Reena H. Doshi³, Melissa Dahlke³, Sylvia Tangney¹, Nicholas Ida¹, Gloire Mbaka Onya⁴, Armand Mutwadi⁵, Kamy Musene⁴, Christophe Luhata⁶, Didine Kaba², Anne W. Rimoin¹

¹University of California - Los Angeles, Los Angeles, USA. ²Ecole de Sante Publique, Université de Kinshasa, Kinshasa, Democratic Republic of Congo. ³Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, USA. ⁴UCLA-DRC Research Program, Kinshasa, Democratic Republic of Congo. ⁵Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo. ⁶National Expanded Program for Immunization, Kinshasa, Democratic Republic of Congo

[P2.22]

Characterization of adverse events of special interest associated with RTS,S/AS01 malaria vaccine during the introduction into routine immunisation in Malawi

Kondwani Mmanga¹, Esther Chirwa², Mike Chisema², Rhoda Chado², Lapani Chisi¹, Joseph Magoola³, Sandra Kiplagat⁴, Jane Gidudu⁴

¹African Field Epidemiology Network, Lilongwe, Malawi. ²Ministry of Health, Expanded Programme on Immunisation, Lilongwe, Malawi. ³African Field Epidemiology Network, Kampala, Uganda. ⁴Centers for Disease Control and Prevention, Atlanta, USA

[P2.23]

Adverse events and its possible causes following primary COVID-19 vaccination using “Pfizer-BioNtech” vaccines: Single center experience in Lithuania

Jolanta Sauserienė, Lukas Mackus, Ida Liseckienė, Leonas Valius, Danielius Serapinas

Lithuanian University of Health Sciences, Kaunas, Lithuania

[P2.25]

Suggestive silicon dioxide nanoparticle (SiO₂) concentration to pulse monocyte-derived dendritic cells *in vitro*

Bruna Tiaki Tiyo¹, Laís Teodoro da Silva¹, Gabriela Justamante Handel Schmitz¹, Jonnatan Julival dos Santos², Sérgio Hiroshi Toma², Marcos Camargo Knirsch³, Marco Antonio Stephano³, Koiti Araki², Telma Miyuki Oshiro¹, Alberto José da Silva Duarte¹

¹Laboratory of Dermatology and Immunodeficiencies, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. ²Laboratory of Supramolecular Chemistry and Nanotechnology, Institute of Chemistry, University of Sao Paulo, Sao Paulo, Brazil. ³Immunobiological and Biopharmaceutical Laboratory, Pharmaceutical-Biochemistry Technology Department, School of Pharmaceutical Science, University of Sao Paulo, Sao Paulo, Brazil

[P2.26]

Serious underlying medical conditions and COVID-19 vaccine hesitancy

Daphne Day^{1,2}, Lisa Grech², Mike Nguyen^{1,2}, Nathan Bain¹, Alastair Kwok^{1,2}, Sam Harris³, Hieu Chau⁴, Bryan Chan^{5,6}, Richard Blennerhassett^{7,8}, Louise Nott⁹, Nada Hamad^{10,11,12}, Annette Tognela¹³, David Hoffman¹⁴, Amelia McCartney^{1,2}, Kate Webber^{1,2}, Jennifer Wong^{2,15}, Craig Underhill^{16,17}, Bao Sheng Loe¹⁸, Daniel Freeman^{19,20}, Eva Segelov^{1,2}

¹Department of Oncology, Monash Health, Clayton, VIC, 3168, Australia. ²Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, 3168, Australia. ³Department of Medical Oncology, Bendigo Health, Bendigo, VIC, 3550, Australia. ⁴Department of Oncology, Latrobe Regional Hospital, Traralgon, VIC, 3844, Australia. ⁵Department of Oncology, Sunshine Coast Hospital and Health Service, Birtinya, QLD, 4575, Australia. ⁶School of Medicine, Griffith University, Birtinya, QLD, 4575, Australia. ⁷Central Coast Haematology, North Gosford, NSW, 2250, Australia. ⁸School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, 2308, Australia. ⁹Icon Cancer Centre Hobart, Hobart, TAS, 7000, Australia. ¹⁰Department of Haematology, St Vincent's Hospital Sydney, Darlinghurst, NSW, 2010, Australia. ¹¹School of Clinical Medicine, Medicine & Health, University of New South Wales, Kensington, NSW, 2052, Australia. ¹²School

of Medicine, University of Notre Dame Australia, Chippendale, NSW, 2007, Australia. ¹³Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, NSW, 2560, Australia. ¹⁴Dr David Hoffman, Fairfield, NSW, 2165, Australia. ¹⁵Department of Diabetes and Vascular Medicine, Monash Health, Clayton, VIC, 3168, Australia. ¹⁶Border Medical Oncology, Albury, NSW, 2640, Australia. ¹⁷Rural Medical School, University of New South Wales, Albury, NSW, 2640, Australia. ¹⁸The Psychometrics Centre, University of Cambridge, Cambridge CB2 1AG, UK. ¹⁹Department of Psychiatry, University of Oxford, Oxford OX3 7JX, UK. ²⁰Oxford Health National Health Service Foundation Trust, Oxford OX3 7JX, UK

[P2.27]

Scale for trust and intention to vaccinate (STRIVE): Mixed methods research to understand the role of trust in vaccine decision-making
Lauren Rauh, MPH, Amanda Pierz, MPH, Dima Masoud, MPH, Alanna Kate Cruz, MS, P. Chris Palmedo, PhD, MBA, Scott C Ratzan, MD, MPA
City University of New York Graduate School of Public Health and Health Policy, New York, USA

[P2.28]

COVID-19 vaccine hesitancy and status in people with diabetes

Lisa Grech¹, Holly Wang², Jennifer Wong^{1,2}, David Hoffman³, Barbora de Courten^{1,2}, Brett Sillars⁴, Mark Savage⁵, Alastair Kwok^{1,6}, Mike Nguyen^{1,6}, Nathan Bain⁶, Daphne Day^{1,6}, Eva Segelov^{1,6}
¹Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, 3168, Australia. ²Department of Diabetes and Vascular Medicine, Monash Health, Clayton, VIC, 3168, Australia. ³Dr David Hoffman, Fairfield, NSW, 2165, Australia. ⁴Department of Endocrinology, Sunshine Coast Hospital and Health Service, Birtinya, QLD, 4575, Australia. ⁵Department of Endocrinology, Bendigo Health, Bendigo, VIC, 3550, Australia. ⁶Department of Oncology, Monash Health, Clayton, VIC, 3168, Australia

[P2.29]

COVID-19 vaccine uptake, intent, hesitancy and disease-related beliefs in people with multiple sclerosis

Lisa Grech¹, Antony Winkel^{2,3}, Ernest Butler^{1,4}, Michelle Allan⁴, Alastair Kwok^{1,5}, Mike Nguyen^{1,5}, Nathan Bain⁵, Daphne Day^{1,5}, Eva Segelov^{1,5}
¹Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, 3168, Australia. ²Department of Neurology, Sunshine Coast Hospital and Health Service, Birtinya, QLD, 4575, Australia. ³School of Medicine, Griffith University, Birtinya, QLD, 4575, Australia. ⁴Monash Neurology, Monash Health, Clayton, VIC, 3168, Australia. ⁵Department of Oncology, Monash Health, Clayton, VIC, 3168, Australia

[P2.30]

In vitro screening of mRNA vaccine formulations for application in poultry and pet birds

Anne De Mevst¹, Pieter De Clercq¹, Beatriz Dias Barbieri², Robin Shattock², Niek Sanders¹, Koen Raemdonck¹, Daisy Vanrompay¹
¹University Ghent, Ghent, Belgium. ²Imperial College London, London, UK

[P2.31]

Comparative risk of myocarditis and pericarditis following SARS CoV2 vaccination with second dose of BNT162b2 and mRNA-1273 COVID-19 vaccines: a retrospective analysis

Zaeema Naveed¹, Julia Li¹, James Wilton², Michelle Spencer³, Monika Naus³, Héctor García¹, Naveed Janjua^{1,3}
¹University of British Columbia, Vancouver, Canada. ²British Columbia Centre for Disease Control, Vancouver, Canada. ³British Columbia Centre for Disease Control, Vancouver, Canada

[P2.32]

Clarity of information related to the COVID-19 vaccine among healthcare workers in the Democratic Republic of Congo

Sylvia Tangney¹, Nicole Hoff¹, Dalau Nkamba², Reena Doshi³, Angelica Barral¹, Gloire Mbaka⁴, Nick Ida¹, Kamy Musene⁴, Armand Mutwadi², Melissa Dahlke³, Christophe Luhata⁵, Didine Kaba², Anne Rimoin¹
¹University of California, Los Angeles, Los Angeles, USA. ²Kinshasa School of Public Health, Kinshasa, Democratic Republic of Congo. ³Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, USA. ⁴UCLA-DRC Health Research and Training Program, Kinshasa, Democratic Republic of Congo. ⁵Expanded Programme for Immunization, Ministry of Health, Kinshasa, Democratic Republic of Congo

[P2.33]

Increasing public confidence in COVID-19 vaccination in South Africa through monitoring of adverse events following immunisation and vaccine safety surveillance communication

Johanna Meyer^{1,2}, Marione Schonfeldt³, Rosemary Burnett^{4,2}, Vienie Botha⁵, Joanne Cornelissen⁵, Ndimuhulu Dowelani³, Yuveng Gounden⁶, Nombulelo Leburu³, Mafora Matlala⁶, Ntokozo Msiza⁶, Naseera Pickard³, Victoria Sekiti⁶
¹Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa. ²South African Vaccination and Immunisation Centre, Sefako Makgatho Health Sciences University, Pretoria, South Africa. ³National Department of Health, Pretoria, South Africa. ⁴Department of Virology, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria, South Africa. ⁵Government Communication and Information System, Pretoria, South Africa. ⁶South African Health Products Regulatory Authority, Pretoria, South Africa

[P2.34]

In silico identification of antigenic epitopes in Iron-Regulated Surface Determinant B (IsdB) protein from Staphylococcus aureus, as a vaccine candidate to prevent bovine mastitis

Camila Renjifo-Ibañez, Sabrina Jimenez, Ligia Torres
AGROSAVIA, Mosquera, Colombia

[P2.35]

Roadmap to the manufacture of vaccines in Colombia: decision matrix based on technologies available around the world

Camila Renjifo-Ibañez, Sabrina Jimenez, David Lopez, Andrea Navarrete, Ligia Torres, Camilo Baez, Jenny Moreno, Diana Rojas, Angelica Bazurto, Rocío Herrera
AGROSAVIA, Mosquera, Colombia

[P2.36]

COVID-19 vaccine acceptance and hesitancy among healthcare workers in Cape Town, South Africa

Samuel Muabe Alobwede¹, Charles S Wiysonge², Patrick de Marie C Katoto³, Elvis B Kidzeru⁴, Evelyn N Lumngwena⁵, Sara Cooper⁶, Muki S Shey⁷
¹Department of Medicine, Faculty of Health Sciences and Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa, Cape Town, South Africa. ²HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa, Cape Town, South Africa. ³Centre for General Medicine and Global Health, Department of Medicine, University of Cape Town, Cape Town, South Africa, Cape Town, South Africa. ⁴Hair and Skin Research Laboratory, Division of Dermatology, Department of Medicine, Faculty of Health Sciences and Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa, Cape Town, South Africa. ⁵School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa, Johannesburg, South Africa. ⁶Cochrane South Africa, South African Medical Research Council, Francie van Zijl Drive, Parow Valley, Cape Town, South Africa, Cape Town, South Africa. ⁷Wellcome Centre for Infectious Disease Research in Africa (CIDRI-Africa), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, Cape Town, South Africa

[P2.37]

A re-engineered adenovirus 5 (Ad5) vector for rapid production of Ad5 vaccines expressing a new vaccine payload

Stephen Chiweshe, William Golde

Moredun Research Institute, Edinburgh, UK

[P2.38]

Occurrence of BNT162b2 vaccine adverse reactions is associated with enhanced SARS-CoV-2 IgG antibody response

Yoav Rechavi¹, Moshe Shashar^{2,3}, Jonathan Lellouche⁴, Moshe Yana⁵, Daniel Yakubovich^{6,7}, Nechama Sharon⁵

¹Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. ²Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. ³Nephrology Section, Netanya, Israel. ⁴Clinical Laboratories Department, Netanya, Israel. ⁵Pediatric Hemato-Oncology Department, Laniado Hospital, Netanya, Israel. ⁶Department of Neonatology, Schneider Children's Hospital, Petach Tikva, Israel. ⁷Preterm Follow-Up Clinic, Sanz Medical Center, Laniado Hospital, Netanya, Israel

[P2.39]

Controlled release vaccine implants for simultaneous delivery of priming and booster immunisations of a tetanus vaccine in sheep

Freya Russell, Logan Trim, Flavia Medeiros Savi, Craig Simon, Tim Dargaville, Dietmar Huttmacher, Kenneth Beagley

Queensland University of Technology, Brisbane, Australia

[P2.40]

A pandemic of distrust: inside El Paso's community-based fight against vaccine hesitancy

Caroline Christmann, Reghan Conrey, Nhu Thao Galván

Baylor College of Medicine, Houston, USA

[P2.41]

Measuring psychosocial determinants of vaccination confidence and behavior in healthcare professionals: validating the Pro-VC-Be short-form tool

Amanda Garrison¹, Lisa Fressard¹, Linda Karlsson², Anna Soveri², Angelo Fasce³, Stephan Lewandowsky^{4,5}, Philipp Schmid⁶, Arnaud Gagneur^{7,8}, Eve Dubé⁹, Pierre Verger¹

¹Observatoire Régional de la Santé, Marseille, France. ²University of Turku, Turku, Finland. ³University of Coimbra, Coimbra, Portugal. ⁴University of Bristol, Bristol, UK. ⁵University of Western Australia, Perth, Australia. ⁶University of Erfurt, Erfurt, Germany. ⁷Centre de Recherche du CHUS, Sherbrooke, Canada. ⁸Université de Sherbrooke-Campus de la Santé, Sherbrooke, Canada. ⁹Laval University, Quebec City, Canada

[P2.42]

Uncovering the possibilities of self-amplifying RNA in vaccine development to tackle future viral outbreaks and potential pandemics

Aster Vandierenonck, Itishri Sahu, Katrien Poelaert, Sophie Valembois, Sean McCafferty, Leonie wyffels, AKM Ashiqul Haque

Ziphys Vaccines NV, Merelbeke, Belgium

[P2.43]

A systematic approach using behavior change wheel to map the influenza vaccine decision and design intervention addressing vaccine hesitancy among Chinese college students in the UK

Lan Li, Caroline E. Wood, Patty Kostkova

University College London, London, UK

[P2.44]

Investigation of cell-mediated immunity after SARS-CoV-2 infection in vaccinated health care workers

Sara Caldrea, Silvia Accordini, Natalia Tiberti, Eleonora Rizzi, Stefano Tais, Concetta Castilletti, Chiara Piubelli

IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy

[P2.45]

Expanding vaccine education to allied health professionals: implementation and assessment of an interdisciplinary education model to address COVID-19 vaccine disparities

Klaus Heyer¹, Sara Al-Dair², Alaa Khalil¹

¹Nunez Community College, Chalmette, USA. ²Xavier University of Louisiana, New Orleans, USA

[P2.46]

Vaccine hesitancy – in terms of attitude, awareness and practice – related to childhood vaccination among Albanian parents

Enkeleza Gjini¹, Irsida Mehmeti¹, Stefania Moramarco², Maria Chiara Carestia³, Fabian Cenko⁴, Alban Ylli⁵, Leonardo Palombi², Ersilia Buonomo³

¹Catholic University "Our Lady of Good Counsel", Tirane, Albania. ²University of Rome "Tor Vergata", Rome, Italy. ³University of Rome "Tor Vergata", Rome, Italy.

⁴Catholic University "Our Lady of Good Counsel", Tirane, Albania. ⁵Tirana Medical University, Tirane, Albania

[P2.47]

Preclinical models for the assessment of vaccine efficacy against hazard group 4 pathogens

Linda Easterbrook, Stuart Dowall, Roger Hewson

UKHSA, Porton, UK

[P2.49]

A new role for South African school teachers as positive influencers of human papillomavirus vaccination decisions

Thuto Christine Bodibe¹, Johanna Catherina Meyer^{1,2}, Languta Angela Khosa¹, Rosemary Burnett^{3,2}

¹Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa. ²South African Vaccination and Immunisation Centre, Sefako Makgatho Health Sciences University, Pretoria, South Africa. ³Department of Virology, School of Medicine, Sefako Makgatho Health Sciences University, Pretoria, South Africa

[P2.50]

HIV peptides selection for the development of a therapeutic vaccine for people living with HIV

Gabriela Justamante Händel Schmitz¹, Laís Teodoro da Silva¹, Bruna Tiaki Tiyo¹, Tatiana Garcia-Bates², Robbie B. Mailliard², Telma Miyuki Oshiro¹, Alberto José da Silva Duarte¹

¹Laboratory of Dermatology and Immunodeficiencies, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil. ²Department of Infectious Diseases and Microbiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, USA

[P2.51]
Sustained childhood vaccination uptake despite a revised national childhood immunization schedule in an urban Asian community amidst the COVID-19 pandemic

Ngiap Chuan Tan, Qifan Tan, Wai Keong Aau, Chung Wai Ng
SingHealth Polyclinics, Singapore, Singapore

[P2.52]
Synthesis of human parainfluenza virus type 2 nucleoprotein ring-like structures in *Escherichia coli*

Zrinka Matić, Dušica Vujaklija, Maja Šantak, Saša Kazazić
Ruđer Bošković Institute, Zagreb, Croatia

[P2.53]
The influence of COVID-19 risk perceptions and vaccination status on the number of social contacts in 16 European countries

James Wambua¹, Neilshan Loedy¹, Christopher I Jarvis², Kerry LM Wong³, Christel Faes¹, Bastian Prasse⁴, Frank Sandmann⁴, Rene Niehus⁴, Helen Claire Johnson⁴, W. John Edmunds³, Philippe Beutels⁵, Niel Hens¹, Pietro Coletti¹
¹Hasselt University, Hasselt, Belgium. ²London School of Hygiene and Tropical Medicine, London, UK. ³London School of Hygiene and Tropical Medicine International Centre for Eye Health, London, UK. ⁴European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden. ⁵Antwerp University, Antwerp, Belgium

[P2.54]
Manufacturing and analytical development of a sustainable vaccine against invasive nontyphoidal salmonellosis and typhoid fever

Antonia De Felice, Vittoria Marchetti, Emilia Cappelletti, Francesca Necchi, Federico Pippi, Maria Grazia Aruta, Francesco Citiulo, Alessandra Acquaviva, Luigi Sollai, Carlo Giannelli, Omar Rossi, Francesco Berlanda Scorza, Anna Maria Colucci, Rocio Canals Alvarez
Gsk Vaccines Institute for Global Health, Siena, Italy

[P2.55]
Comparison of intramuscular and oral administration of an attenuated live marker classical swine fever vaccine (Flc-LOM-BE^{ns})

SeEun Choe, Ki-Sun Kim, Jae-Hui kim, Bang-Hun Hyun, Dong-Jun An
Viral disease division, Animal and Plant Quarantine Agency, Gimcheon-si, Republic of Korea

[P2.56]
Determinants and perceptions of Bacille Calmette-Guerin scarification among healthcare workers

Paola Villanueva^{1,2,3}, Nicole Messina^{2,1}, Laure Pittet^{2,1,3}, Nigel Curtis^{2,1,3}
¹The University of Melbourne, Melbourne, Australia. ²Murdoch Children's Research Institute, Melbourne, Australia. ³The Royal Children's Hospital, Melbourne, Australia

[P2.57]
Combined DNA vaccination with chimeric HBV-HCV virus-like particles and NS3/4A protease induces a potent humoral and cellular responses against HCV

Anna Czarnota, Aleksandra Raszplewicz, Alicja Chmielewska, Krystyna Bieńkowska-Szewczyk, Katarzyna Grzyb
Laboratory of Virus Molecular Biology, Intercollegiate Faculty of Biotechnology of the University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland

[P2.58]
Strep a vaccine: from formulation development to toxicology lot production

Emilia Cappelletti, Xhenti Ferhati, Giulia Maria Massantini, Vittoria Marchetti, Antonia De Felice De Felice, Alessandra Acquaviva, Luca Rovetini, Federico Pippi, Filomena De Luca, Francesco Citiulo, Omar Rossi, Martina Carducci, Luisa Massai, Carlo Giannelli, Luigi Sollai, Giulia Iannello, Elena Fiorentini, Francesca Necchi, Danilo Gomes Moriel, Anna Maria Colucci
GSK Vaccines Institute for Global Health, Siena, Italy

[P2.59]
Use of catch-up vaccinations in the second year of life (2YL) platform to close immunity gaps: a secondary DHS analysis in Pakistan, Philippines, and South Africa

Porcia Manandhar¹, Kathleen Wannemuehler², M. Carolina Danovaro-Holliday³, Laura Nic Lochlainn³, Stephanie Shendale³, Samir V. Sodha³
¹Johns Hopkins University, Baltimore, MD, USA. ²University of Wisconsin-Madison, Madison, WI, USA. ³World Health Organization, Geneva, Switzerland

[P2.60]
Malaria vaccine hesitancy in Nigeria: prevalence, determinants and reasons from a nationwide cross-sectional survey

Sahabi Kabir Sulaiman¹, Muhammad Sale Musa¹, Fatima Ismail Tsiga-Ahmed², Abdulwahab Kabir Sulaiman^{3,4}, Farouq Muhammad Dayyab⁵, Abdulaziz Tijjani Bako⁶
¹Department of Medicine, Yobe State University Teaching Hospital, Damaturu, Nigeria. ²Department of Community Medicine, Bayero University Kano/Aminu Kano Teaching Hospital, Kano, Nigeria. ³Murtala Muhammad Specialist Hospital, Kano, Nigeria. ⁴Kwanar Dawaki COVID-19 Isolation Center, Kano, Nigeria. ⁵Infectious Diseases Hospital, Kano, Nigeria. ⁶Center for Outcomes Research, Houston Methodist, Houston, Texas, USA

[P2.61]
COVID-19 vaccine hesitancy among people living with HIV (PLHIV) in a low-resource setting: a multi-center study of prevalence, correlates and reasons

Sahabi Kabir Sulaiman¹, Muhammad Sale Musa¹, Farouq Muhammad Dayyab², Fatima Ismail Tsiga-Ahmed³, Abdulwahab Kabir Sulaiman^{4,5}, Abdulaziz Tijjani Bako⁶
¹Department of Medicine, Yobe State University Teaching Hospital, Damaturu, Nigeria. ²Infectious Diseases Hospital, Kano, Nigeria. ³Department of Community Medicine, Bayero University Kano/Aminu Kano Teaching Hospital, Kano, Nigeria. ⁴Murtala Muhammad Specialist Hospital, Kano, Nigeria. ⁵Kwanar Dawaki COVID-19 Isolation Center, Kano, Nigeria. ⁶Center for Outcomes Research Houston Methodist, Houston, Texas, USA

[P2.62]
Proteomic analysis of extracellular vesicles in response to baculovirus infection of a *Trichoplusia ni* cell line

Christina Sophie Hausjell¹, Wolfgang Ernst¹, Clemens Grünwald-Gruber², Reingard Grabherr¹
¹Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria. ²Core Facility Mass Spectrometry, University of Natural Resources and Life Sciences, Vienna, Austria

[P2.63]
Factors that determine a country's readiness to deploy a vaccine in a routine programme: A systematic scoping review

Rachel Mitrovich¹, Luke Baxter², Amanda Eiden¹, Lindsay Hermany¹, Alexandra Bhatti¹, Aomesh Bhatt²
¹Merck & Co., Inc., Rahway, USA. ²University of Oxford, Oxford, UK

[P2.64]

Psychological characteristics, social norms, and behavioral nudges of COVID-19 vaccine hesitancy and vaccination behavior: a cross-sectional survey among older and young adults in China

Rui Peng

Tsinghua University School of Public Policy and Management, Beijing, China. Tsinghua University Center for Crisis Management Research and Social Risk Assessment in China, Beijing, China. Harvard Kennedy School, Ash Center for Democratic Governance & Innovation, Rajawali Foundation Institute, Cambridge, USA

[P2.65]

Development of a Strep A vaccine: immuno/safety profile of an adjuvanted formulation with Alum

Francesco Citiulo, Emilia Cappelletti, Claudia Vitali, Martina Carducci, Luisa Massai, Luigi Sollai, Omar Rossi

GSK Vaccines Institute for Global Health, Siena, Italy

[P2.66]

Inactivated severe fever with thrombocytopenia syndrome virus vaccine elicits protective immunity via CD8⁺ T cell-mediated immune response in mice

Seok-Chan Park¹, Jun Young Park², Byungkwan Oh¹, Dong-Seob Tark², Bumseok Kim¹

¹Biosafety Research Institute and College of Veterinary Medicine, Jeonbuk National University, Iksan, Republic of Korea. ²Korea Zoonosis Research institute, Jeonbuk National University, Iksan, Republic of Korea

[P2.67]

Low energy electron irradiation efficiently inactivates pathogens in liquids and is a promising method for the generation of vaccines

Jasmin Fertey¹, Leila Issmail¹, Julia Finkensieper¹, Martin Thoma², Ulla Koenig³, Thomas Grunwald¹, Sebastian Ulbert¹

¹Fraunhofer-Institute for Cell Therapy and Immunology, Leipzig, Germany. ²Fraunhofer Institute for Manufacturing Engineering and Automation, Stuttgart, Germany. ³Fraunhofer-Institute for Organic Electronics, Electron Beam and Plasma Technology, Dresden, Germany

[P2.68]

'Disgusting diseases': purity framing to increase attitudes towards routine childhood immunization among parents in Argentina

Maike Winters^{1,2}, Sarah Christie³, Hannah Melchinger³, Nahuel Arias⁴, Luciana Lirman⁴, Angus Thomson⁵, Saad Omer³

¹Yale Institute for Global Health, New Haven, CT, USA. ²Yale School of Medicine, New Haven, CT, USA. ³Yale Institute for Global Health, New Haven, USA. ⁴UNICEF Argentina, Buenos Aires, Argentina. ⁵United States Fund for UNICEF, New York, NY, USA

[P2.69]

Corona Sao Caetano Initiative: an innovative public health response to the COVID-19 pandemic facilitating the development of surveillance and vaccine trials

Fabio Lea^{1,2}, Maria Cassia Mendes-Correa^{3,4}, Regina Maura Grespan^{5,1}, Ligia Capuani^{3,6}, Helves Domingues⁶, Erika Manuli^{3,1}, Sheila Mateos¹, Monica Conde¹, Cesar de Almeida-Neto¹, Silvia Costa^{3,4}, Ester Sabino^{4,1}

¹Universidade Municipal de Sao Caetano do Sul, Sao Caetano do Sul, Brazil. ²Instituto Nacional de Câncer José de Alencar, Rio de Janeiro, Brazil. ³Departamento de Doenças Infecciosas e Parasitárias, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil. ⁴Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil. ⁵Secretaria Municipal de Saúde, Prefeitura Municipal de São Caetano do Sul, Sao Caetano do Sul, Brazil. ⁶Brasil & MRS Modular Research System Ltda., Sao Paulo, Brazil

[P2.70]

COVID-19 vaccination hesitancy in patients on dialysis: a systematic review and meta-analysis

Eustachio Cuscianna¹, Silvio Tafuri², Giovanni Migliore³, Pasquale Stefanizzi², Francesco Paolo Bianchi³

¹University of Bari School of Specialization in Hygiene and Preventive Medicine, Bari, Italy. ²University of Bari Interdisciplinary Department of Medicine, Bari, Italy. ³University Hospital Polyclinic of Bari, Bari, Italy

[P2.71]

Long-term immunogenicity of anti-hepatitis B vaccine in Italian healthcare workers: a systematic review and meta-analysis

Francesco Paolo Bianchi, Luigi Vimercati, Andrea Martinelli, Pasquale Stefanizzi, Cinzia Annatea Germinario, Silvio Tafuri

Interdisciplinary Department of Medicine, University of Bari, Bari, Italy

[P2.72]

Manufacturing and use of inactivated autogenous vaccines: an Italian experience

Gianfilippo Alessio Clemente, Elena Stoppiani, Aldo Bonomi, Annalisa Ghizzardi, Fusi Francesca, Luigi Bertocchi, Sara Rota Nodari

Reparto Produzione e Controllo Materiale Biologico, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna, Brescia, Italy

[P2.73]

Do frail adults respond to HBV vaccination? the real experience of the vaccination center at the Ospedale Policlinico San Martino, Genoa

Elvira Massaro¹, Marco Bongiovanni¹, Giulia Gatti¹, Oriana Ferrante¹, Erika Zumerle¹, Marianna Scarpaleggia¹, Alessandra Bocchio¹, Mariachiara Sgariglia¹, Laura Sticchi^{1,2}, Andrea Orsi^{1,2}

¹Department of Health Sciences, University of Genoa, Genoa, Italy. ²Hygiene Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

[P2.74]

Estimating the optimal age of measles vaccination in infants: a mathematical modelling study

Elizabeth Goult¹, Laura Andrea Barrero Guevara^{1,2}, Sylvie Escolano³, Matthieu Domenech de Cellès¹

¹Max Planck Institute for Infection Biology, Berlin, Germany. ²Institute of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany. ³Centre de Recherche en Épidémiologie et Santé des Populations, INSERM, Paris, France

[P2.75]

Poor practices of healthcare workers regarding post-exposure prophylaxis of dog-bite related rabies at primary health care facilities in a rural district in South Africa

Kgodumo Mabilo^{1,2}, Mncengeli Sibanda^{1,3}, Rosemary Burnett^{1,3}, Johanna Meyer^{1,3}

¹Sefako Makgatho Health Sciences University, Pretoria, South Africa. ²Thabazimbi Hospital, Thabazimbi, South Africa. ³South African Vaccination and Immunisation Centre, Pretoria, South Africa

[P2.76]

Development of foot-and-mouth disease intradermal vaccine for early protection in Swine

Dong-Wan Kim, Gi Youn Cho, Gyeongmin Lee, Tae Gwan Lim, Ho-Young Kwak, Jae-Won Byun, Jong-Hyeon Park, SungHan Park

Animal and Plant Quarantine Agency, Gimcheon City, Republic of Korea